Idexx Laboratories Inc (IDXX) — Analysis Summary
Idexx Laboratories Inc (IDXX) has a market cap of $43.72B with year-over-year revenue growth of +10.4%. Net margin stands at 24.6%. The stock trades at a P/E ratio of 38.4.
Key Takeaways
- Revenue changed +10.4% year-over-year
- Net margin of 24.6%
- P/E ratio of 38.4
Compared to other companies in the IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES sector, IDXX posted revenue growth of +10.4% and trades at a P/E of 38.4.
Idexx Laboratories Inc (IDXX)
UPDATED — ET · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsNo Major Flags
No major credit, margin, or trend red flags were triggered from the latest filings.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx derives roughly 35% of its revenue from outside the United States.
Sector
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Employees
11,000
Headquarters
WESTBROOK, ME
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.